Primary breast diffuse large B ‐cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group

ConclusionCollectively, our results indicate combined modality therapy including rituximab-containing immunochemotherapy and consolidative breast RT is a promising approach for PB-DLBCL, while HD-MTX is useful for preventing CNS relapse.

Source: Cancer Medicine - November 24, 2023 Category: Cancer & Oncology Authors: Huawei Weng, Prem Raj Shrestha, Huangming Hong, Zegeng Chen, Le Yu, Yuyi Yao, Zhihui Zhang, Liqun Zou, Bo Zhu, Hui Zhou, Xianling Liu, Yao Liu, Hongqiang Guo, He Huang, Tongyu Lin Tags: RESEARCH ARTICLE Source Type: research